KELLIE WYDRINSKI: Open Payments
NPI 1184471377 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,426 in 23 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $676 · 2025 $1,426
Food & beverage: $1,426
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 5 | $392 |
| Mallinckrodt Hospital Products Inc. | 5 | $190 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $168 |
| Madrigal Pharmaceuticals | 1 | $141 |
| Regeneron Healthcare Solutions, Inc. | 2 | $135 |
| Gilead Sciences, Inc. | 1 | $119 |
| Ardelyx, Inc. | 1 | $116 |
| Ipsen Biopharmaceuticals, Inc | 1 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Daiichi Sankyo Inc. | 1 | $20 |
Products named: TREMFYA, TERLIVAZ, XIFAXAN, REZDIFFRA, Livdelzi, IBSRELA, IQIRVO, ENTYVIO.
Industry payments across GA — which companies pay providers there.
